353 related articles for article (PubMed ID: 31567189)
21. Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors.
Rudzinski ER; Lockwood CM; Stohr BA; Vargas SO; Sheridan R; Black JO; Rajaram V; Laetsch TW; Davis JL
Am J Surg Pathol; 2018 Jul; 42(7):927-935. PubMed ID: 29683818
[TBL] [Abstract][Full Text] [Related]
22. Clinicopathological findings of pediatric NTRK fusion mesenchymal tumors.
Kang J; Park JW; Won JK; Bae JM; Koh J; Yim J; Yun H; Kim SK; Choi JY; Kang HJ; Kim WS; Shin JH; Park SH
Diagn Pathol; 2020 Sep; 15(1):114. PubMed ID: 32957984
[TBL] [Abstract][Full Text] [Related]
23. Clinicopathologic and molecular characterization of NTRK-rearranged thyroid carcinoma (NRTC).
Chu YH; Dias-Santagata D; Farahani AA; Boyraz B; Faquin WC; Nosé V; Sadow PM
Mod Pathol; 2020 Nov; 33(11):2186-2197. PubMed ID: 32457407
[TBL] [Abstract][Full Text] [Related]
24. NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.
Prasad ML; Vyas M; Horne MJ; Virk RK; Morotti R; Liu Z; Tallini G; Nikiforova MN; Christison-Lagay ER; Udelsman R; Dinauer CA; Nikiforov YE
Cancer; 2016 Apr; 122(7):1097-107. PubMed ID: 26784937
[TBL] [Abstract][Full Text] [Related]
25. NTRK gene rearrangements are highly enriched in MLH1/PMS2 deficient, BRAF wild-type colorectal carcinomas-a study of 4569 cases.
Chou A; Fraser T; Ahadi M; Fuchs T; Sioson L; Clarkson A; Sheen A; Singh N; Corless CL; Gill AJ
Mod Pathol; 2020 May; 33(5):924-932. PubMed ID: 31792356
[TBL] [Abstract][Full Text] [Related]
26. Testing algorithm for identification of patients with TRK fusion cancer.
Penault-Llorca F; Rudzinski ER; Sepulveda AR
J Clin Pathol; 2019 Jul; 72(7):460-467. PubMed ID: 31072837
[TBL] [Abstract][Full Text] [Related]
27. NTRK-rearranged Cervical Sarcoma: Expanding the Clinicopathologic Spectrum.
Hodgson A; Pun C; Djordjevic B; Turashvili G
Int J Gynecol Pathol; 2021 Jan; 40(1):73-77. PubMed ID: 32044823
[TBL] [Abstract][Full Text] [Related]
28. Infantile NTRK-associated Mesenchymal Tumors.
Davis JL; Lockwood CM; Albert CM; Tsuchiya K; Hawkins DS; Rudzinski ER
Pediatr Dev Pathol; 2018; 21(1):68-78. PubMed ID: 28683589
[TBL] [Abstract][Full Text] [Related]
29. Pan-TRK Immunohistochemistry Is Highly Correlated With NTRK3 Gene Rearrangements in Salivary Gland Tumors.
Csanyi-Bastien M; Lanic MD; Beaussire L; Ferric S; François A; Meseure D; Jardin F; Wassef M; Ruminy P; Laé M
Am J Surg Pathol; 2021 Nov; 45(11):1487-1498. PubMed ID: 33899788
[TBL] [Abstract][Full Text] [Related]
30. The oncogenic roles of NTRK fusions and methods of molecular diagnosis.
Aref-Eshghi E; Lin F; Li MM; Zhong Y
Cancer Genet; 2021 Nov; 258-259():110-119. PubMed ID: 34710798
[TBL] [Abstract][Full Text] [Related]
31. NTRK -Rearranged Uterine Sarcomas: Clinicopathologic Features of 15 Cases, Literature Review, and Risk Stratification.
Costigan DC; Nucci MR; Dickson BC; Chang MC; Song S; Sholl LM; Hornick JL; Fletcher CDM; Kolin DL
Am J Surg Pathol; 2022 Oct; 46(10):1415-1429. PubMed ID: 35713627
[TBL] [Abstract][Full Text] [Related]
32. Primary and Metastatic Melanoma With NTRK Fusions.
Lezcano C; Shoushtari AN; Ariyan C; Hollmann TJ; Busam KJ
Am J Surg Pathol; 2018 Aug; 42(8):1052-1058. PubMed ID: 29683819
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of NTRK expression and fusions in a large cohort of early-stage lung cancer.
Dyrbekk APH; Warsame AA; Suhrke P; Ludahl MO; Zecic N; Moe JO; Lund-Iversen M; Brustugun OT
Clin Exp Med; 2024 Jan; 24(1):10. PubMed ID: 38240952
[TBL] [Abstract][Full Text] [Related]
34. NTRK-Rearranged soft tissue neoplasms: A review of evolving diagnostic entities and algorithmic detection methods.
Surrey LF; Davis JL
Cancer Genet; 2022 Jan; 260-261():6-13. PubMed ID: 34794069
[TBL] [Abstract][Full Text] [Related]
35. Broadening the spectrum of NTRK rearranged mesenchymal tumors and usefulness of pan-TRK immunohistochemistry for identification of NTRK fusions.
Brčić I; Godschachner TM; Bergovec M; Igrec J; Till H; Lackner H; Scheipl S; Kashofer K; Brodowicz T; Leithner A; Szkandera J; Liegl-Atzwanger B
Mod Pathol; 2021 Feb; 34(2):396-407. PubMed ID: 32860002
[TBL] [Abstract][Full Text] [Related]
36. NTRK fusion-positive cancers and TRK inhibitor therapy.
Cocco E; Scaltriti M; Drilon A
Nat Rev Clin Oncol; 2018 Dec; 15(12):731-747. PubMed ID: 30333516
[TBL] [Abstract][Full Text] [Related]
37. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features.
Pai RK; Jayachandran P; Koong AC; Chang DT; Kwok S; Ma L; Arber DA; Balise RR; Tubbs RR; Shadrach B; Pai RK
Am J Surg Pathol; 2012 May; 36(5):744-52. PubMed ID: 22314188
[TBL] [Abstract][Full Text] [Related]
38. NTRK point mutations and their functional consequences.
Rogers C; Morrissette JJD; Sussman RT
Cancer Genet; 2022 Apr; 262-263():5-15. PubMed ID: 34972036
[TBL] [Abstract][Full Text] [Related]
39. The Use of Pan-Tropomyosin Receptor Kinase Immunohistochemistry as a Screening Tool for the Detection of Neurotrophic Tropomyosin-Related Kinase Fusions: Real-World Data from a National Multicentric Retrospective Study.
Van Bockstal MR; Beniuga G; Craciun L; Creytens D; Dedeurwaerdere F; Delvenne P; Demetter P; De Wiest B; Dewinne K; Habran L; Pauwels P; Theate I; Vander Borght S; Van Der Steen K; Weynand B
Pathobiology; 2022; 89(6):393-406. PubMed ID: 35350025
[TBL] [Abstract][Full Text] [Related]
40. Applicability of pan-TRK immunohistochemistry for identification of NTRK fusions in lung carcinoma.
Strohmeier S; Brcic I; Popper H; Liegl-Atzwanger B; Lindenmann J; Brcic L
Sci Rep; 2021 May; 11(1):9785. PubMed ID: 33963267
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]